Poolbeg Pharma (POLB) , a clinical-stage biopharma company focused on infectious diseases, announced positive results from lab-based analysis of RSV drug targets and treatments identified as part of its AI programme.
Poolbeg said its team of experts reviewed the comprehensive dataset obtained from the lab and prioritised a select number of RSV drug candidates. The biopharma company is currently exploring the most effective way to progress those prioritised candidates in order to generate the most value.
"The positive outputs from this analysis, and the successful prioritisation of our RSV drug candidates, is a testament to the power of our AI-led drug discovery programme. As we engage in partnering discussions, these results position Poolbeg as a key player in the evolving landscape of AI-driven drug discovery." commented Jeremy Skillington, CEO of Poolbeg Pharma.
View from Vox
More good news from Poolbeg Pharma's AI-led discovery programme and related partnership with OneThree Biotech. The prioritised RSV candidates were identified from a comprehensive dataset in only 10 months - a much shorter timeframe than would have been possible using traditional methods - thanks to the power of AI-accelerated drug discovery. As Poolbeg advances the prioritised candidates, it is continuing partnering discussions with industry leaders interested in the results. Investors should note the JP Morgan Healthcare Conference in San Francisco in January 2024 where some of those discussions may be moved forward.
The global interest in AI-led drug discovery continues to grow, with major pharmaceutical players making substantial investments in the field. Poolbeg's RSV AI programme identified these drug treatment candidates in mere months as AI-led drug discovery greatly accelerates discovery timelines, in turn reducing costs and decreasing risks while simultaneously providing a higher likelihood of success in bringing groundbreaking therapies to patients.
As Poolbeg is on the cutting edge of AI-accelerated drug discovery, we expect near-term upside as its partnering efforts with OneThree Biotech for RSV, and CytoReason for influenza begin to bear fruit. Both are supported by extensive, high-quality datasets ideal for AI analysis.
Follow News & Updates from Poolbeg Pharma: